DEF 14A: BiomX Seeks Stockholder Approval for Key Proposals Including Reverse Stock Split and Share Authorization Increase

BiomX Inc. is urging stockholders to vote on several critical proposals at its upcoming annual meeting, including a reverse stock split authorization and an increase in authorized common stock shares to facilitate recent acquisitions and future growth.

Summary

• BiomX Inc. is holding its 2024 Annual Meeting of Stockholders online on July 9, 2024, to vote on nine proposals.
• Proposal 1 seeks approval for the conversion of 256,887 shares of Series X Non-Voting Convertible Preferred Stock and the exercise of warrants related to the acquisition of Adaptive Phage Therapeutics (APT).
• Proposal 2 aims to approve the amendment and restatement of the company's 2019 Omnibus Long-Term Incentive Plan.
• Proposal 3 requests an amendment to the company's certificate of incorporation to increase the authorized shares of Common Stock from 120,000,000 to 750,000,000.
• Proposal 7 asks for authorization to effect a reverse stock split of the company's outstanding Common Stock at a ratio between 1-for-5 and 1-for-10.
• The remaining proposals cover the election of directors, executive compensation, the frequency of advisory votes on executive compensation, ratification of the auditor, and adjournment of the meeting if necessary.
• The Board of Directors recommends voting FOR Proposals 1, 2, 3, 5, 7, 8 and 9, FOR each director nominee for Proposal 4, and EVERY THREE YEARS for Proposal 6.

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative information. While the acquisition and private placement are positive developments, the company's financial situation and compliance issues temper the overall sentiment.

Positives

• The proposed increase in authorized shares provides flexibility for future corporate actions, including acquisitions and capital raising.
• The reverse stock split could make the company's stock more attractive to a broader range of investors.
• The acquisition of Adaptive Phage Therapeutics, Inc. expands the company's pipeline with two Phase 2 assets.
• The company secured $50 million in a private placement offering, strengthening its balance sheet.

Negatives

• Approval of the conversion proposal will result in significant dilution for existing stockholders, excluding the investors in the private placement.
• The company has a history of losses and a substantial accumulated deficit.
• The company received a notification from NYSE American regarding non-compliance with continued listing standards.
• The company may be required to pay cash to redeem the Series X Preferred Stock if the conversion proposal is not approved.

Risks

• Failure to obtain stockholder approval for the key proposals could limit the company's financing options and strategic flexibility.
• The company's stock may be delisted from NYSE American if it fails to regain compliance with listing standards.
• The market price of the company's common stock may decline after a reverse stock split.
• The company may not have sufficient liquidity to settle a significant amount of the Series X Preferred Stock if required to do so.
• The company's future success depends on its ability to attract, retain and motivate highly-skilled employees.

Future Outlook

The company plans to focus on the development of BX004 and BX211 and will likely require additional funding to support its operating expenses and capital requirements.

Management Comments

• The Board has determined that it is in the best interests of us and our stockholders to seek stockholder approval of the A&R Plan.
• The Board believes that the benefits of providing it with the flexibility to issue shares without delay for any proper business purpose, including as an alternative to an unsolicited business combination opposed by the Board, outweigh the possible disadvantages of dilution and discouraging unsolicited business combination proposals and that it is prudent and in the best interests of stockholders to provide the advantage of greater flexibility which will result from the Authorized Share Increase.

Industry Context

The announcement reflects a trend in the biotech industry where companies seek strategic transactions and financing to advance their clinical programs and maintain financial stability.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, it mentions that the Board considered compensation practices of similar companies when approving the A&R Plan.
• The document also mentions that the Board considered the strength of the balance sheet of the combined company, which includes the cash that BiomX and APT held prior to the Acquisition plus the gross proceeds from the concurrent Private Placement of approximately $50 million.

Related Party Transactions

• The document mentions related-party transactions, including a private placement with existing stockholders and the receipt of warrants and shares of Series X Preferred Stock by certain directors and existing stockholders.

Stakeholder Impact

• Approval of the conversion proposal will result in significant dilution for existing stockholders, excluding the investors in the private placement.
• The reverse stock split could make the company's stock more attractive to a broader range of investors.
• The company's future success depends on its ability to attract, retain and motivate highly-skilled employees.

Next Steps

• Hold the 2024 Annual Meeting of Stockholders on July 9, 2024.
• File the Share Increase Amendment with the Secretary of State of the State of Delaware if approved.
• Prepare and submit a plan of compliance to NYSE American by June 22, 2024.
• Initiate a Phase 2b study in CF patients in the fourth quarter of 2024.
• Obtain stockholder approval for the conversion of Series X Preferred Stock and the exercise of warrants.

Key Dates

Keywords

reverse stock split, share authorization, proxy statement, annual meeting, BiomX, acquisition, warrants, preferred stock, incentive plan, dilution